Muhammad Khalid Khan Niazi
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Image Processing, Computer-Assisted | 14 | 2020 | 244 | 2.900 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2023 | 121 | 2.670 |
Why?
|
| Ki-67 Antigen | 4 | 2023 | 30 | 1.470 |
Why?
|
| Algorithms | 9 | 2022 | 497 | 1.220 |
Why?
|
| Cell Nucleus | 2 | 2018 | 112 | 1.020 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 759 | 1.010 |
Why?
|
| Neoplasms | 2 | 2023 | 695 | 0.970 |
Why?
|
| Lung | 2 | 2015 | 262 | 0.850 |
Why?
|
| Artificial Intelligence | 4 | 2023 | 55 | 0.810 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2019 | 61 | 0.800 |
Why?
|
| Microscopy | 2 | 2019 | 28 | 0.780 |
Why?
|
| Prognosis | 4 | 2024 | 1523 | 0.740 |
Why?
|
| Pathology | 1 | 2019 | 19 | 0.670 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 545 | 0.660 |
Why?
|
| Data Compression | 1 | 2018 | 2 | 0.660 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 21 | 0.620 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2015 | 7 | 0.600 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 194 | 0.600 |
Why?
|
| Neuroblastoma | 1 | 2017 | 33 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 142 | 0.550 |
Why?
|
| Proteomics | 1 | 2017 | 94 | 0.550 |
Why?
|
| Histocytochemistry | 1 | 2016 | 32 | 0.550 |
Why?
|
| Tuberculosis | 1 | 2015 | 15 | 0.520 |
Why?
|
| Humans | 23 | 2024 | 32297 | 0.490 |
Why?
|
| Neutrophils | 1 | 2015 | 118 | 0.490 |
Why?
|
| Granuloma | 1 | 2013 | 25 | 0.470 |
Why?
|
| Lymphocytes | 1 | 2013 | 58 | 0.460 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2010 | 5 | 0.450 |
Why?
|
| Software | 1 | 2013 | 126 | 0.440 |
Why?
|
| Information Storage and Retrieval | 3 | 2020 | 25 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 492 | 0.380 |
Why?
|
| Tympanic Membrane | 2 | 2020 | 6 | 0.370 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2010 | 1 | 0.360 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2010 | 2 | 0.360 |
Why?
|
| Teratogens | 1 | 2010 | 3 | 0.360 |
Why?
|
| Astemizole | 1 | 2010 | 6 | 0.360 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2010 | 10 | 0.360 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 65 | 0.350 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 779 | 0.340 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 222 | 0.330 |
Why?
|
| Phantoms, Imaging | 2 | 2018 | 61 | 0.310 |
Why?
|
| Lymphoma, Follicular | 2 | 2017 | 19 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 213 | 0.260 |
Why?
|
| Cytokines | 2 | 2017 | 262 | 0.250 |
Why?
|
| Female | 12 | 2023 | 20126 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 16 | 0.230 |
Why?
|
| Staining and Labeling | 2 | 2020 | 61 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 849 | 0.210 |
Why?
|
| Otoscopy | 1 | 2020 | 3 | 0.190 |
Why?
|
| Ear Diseases | 1 | 2020 | 8 | 0.190 |
Why?
|
| Otolaryngology | 1 | 2020 | 18 | 0.190 |
Why?
|
| Pattern Recognition, Automated | 2 | 2013 | 35 | 0.180 |
Why?
|
| Feasibility Studies | 2 | 2020 | 294 | 0.180 |
Why?
|
| Mice | 3 | 2015 | 2524 | 0.180 |
Why?
|
| Workflow | 1 | 2019 | 23 | 0.170 |
Why?
|
| Telemedicine | 1 | 2020 | 99 | 0.170 |
Why?
|
| Animals | 5 | 2015 | 7694 | 0.160 |
Why?
|
| Rosacea | 1 | 2019 | 46 | 0.160 |
Why?
|
| Interferon-gamma | 2 | 2015 | 63 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 46 | 0.160 |
Why?
|
| Molecular Imaging | 1 | 2018 | 22 | 0.150 |
Why?
|
| Kidney | 1 | 2022 | 529 | 0.150 |
Why?
|
| Keratoconus | 1 | 2017 | 3 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2019 | 144 | 0.150 |
Why?
|
| Biopsy | 1 | 2018 | 273 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 877 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 128 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2018 | 602 | 0.130 |
Why?
|
| Prostate | 1 | 2016 | 74 | 0.130 |
Why?
|
| Chemokine CXCL5 | 1 | 2015 | 4 | 0.130 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Chemokine CXCL2 | 1 | 2015 | 11 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2017 | 534 | 0.130 |
Why?
|
| Chemokines | 1 | 2015 | 38 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 56 | 0.130 |
Why?
|
| Observer Variation | 3 | 2020 | 109 | 0.130 |
Why?
|
| Hematoxylin | 1 | 2013 | 4 | 0.120 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 5 | 0.120 |
Why?
|
| Cell Count | 1 | 2013 | 52 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 30 | 0.110 |
Why?
|
| Embryo Culture Techniques | 2 | 2010 | 3 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1281 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 1092 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 773 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2013 | 83 | 0.110 |
Why?
|
| Image Enhancement | 2 | 2013 | 75 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1040 | 0.100 |
Why?
|
| Male | 6 | 2020 | 19488 | 0.100 |
Why?
|
| Apoptosis | 1 | 2013 | 368 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 756 | 0.090 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cetirizine | 1 | 2010 | 2 | 0.090 |
Why?
|
| Nitroimidazoles | 1 | 2010 | 4 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2010 | 8 | 0.090 |
Why?
|
| Maternal Exposure | 1 | 2010 | 13 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 32 | 0.090 |
Why?
|
| Pregnancy | 2 | 2010 | 1010 | 0.090 |
Why?
|
| Heart | 1 | 2010 | 182 | 0.080 |
Why?
|
| Rats | 2 | 2010 | 1675 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 337 | 0.080 |
Why?
|
| Handwriting | 1 | 2006 | 2 | 0.070 |
Why?
|
| Biometry | 1 | 2006 | 14 | 0.070 |
Why?
|
| Child | 2 | 2023 | 2472 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2024 | 29 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 40 | 0.060 |
Why?
|
| Habits | 1 | 2023 | 3 | 0.060 |
Why?
|
| Breast | 1 | 2023 | 61 | 0.050 |
Why?
|
| Risk | 1 | 2023 | 325 | 0.050 |
Why?
|
| Health Personnel | 1 | 2023 | 121 | 0.050 |
Why?
|
| Logistic Models | 1 | 2023 | 788 | 0.050 |
Why?
|
| Video Recording | 1 | 2020 | 57 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2020 | 23 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 257 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 462 | 0.040 |
Why?
|
| Face | 1 | 2019 | 30 | 0.040 |
Why?
|
| Adult | 3 | 2020 | 9467 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 95 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 171 | 0.040 |
Why?
|
| Models, Biological | 2 | 2013 | 397 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 2 | 0.040 |
Why?
|
| Entropy | 1 | 2017 | 8 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 190 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 147 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 167 | 0.040 |
Why?
|
| Alleles | 1 | 2017 | 252 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 213 | 0.040 |
Why?
|
| Genotype | 1 | 2017 | 742 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 345 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 600 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 536 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 110 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 4 | 0.030 |
Why?
|
| Diffusion | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cell Communication | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cell Survival | 1 | 2013 | 301 | 0.030 |
Why?
|
| Phenytoin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2010 | 13 | 0.020 |
Why?
|
| Bradycardia | 1 | 2010 | 17 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 736 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 206 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 94 | 0.020 |
Why?
|
| Computer Security | 1 | 2006 | 8 | 0.020 |
Why?
|
| Motion | 1 | 2006 | 13 | 0.020 |
Why?
|
| Online Systems | 1 | 2006 | 13 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 3358 | 0.020 |
Why?
|
| Middle Aged | 1 | 2017 | 11949 | 0.010 |
Why?
|